Editas Medicine (EDIT) News Today → On June 10, Nvidia makes its next big move (From Weiss Ratings) (Ad) Free EDIT Stock Alerts $5.20 +0.03 (+0.58%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 2:00 AM | americanbankingnews.comEquities Analysts Set Expectations for Editas Medicine, Inc.'s FY2024 Earnings (NASDAQ:EDIT)May 31 at 8:25 AM | marketbeat.comBrokers Issue Forecasts for Editas Medicine, Inc.'s FY2024 Earnings (NASDAQ:EDIT)Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities research analysts at Chardan Capital reduced their FY2024 earnings estimates for shares of Editas Medicine in a research report issued on Tuesday, May 28th. Chardan Capital analyst Y. Livshits now forecasts that the company will earn ($May 31 at 5:50 AM | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Price Target Cut to $7.00 by Analysts at Evercore ISIMay 30 at 12:19 PM | marketbeat.comEvercore ISI Trims Editas Medicine (NASDAQ:EDIT) Target Price to $7.00Evercore ISI reduced their price target on Editas Medicine from $15.00 to $7.00 and set an "in-line" rating on the stock in a report on Thursday.May 28, 2024 | finance.yahoo.comAzzur Cleanrooms on Demand™ Grand Opening in Devens, MA Brings Together Local, State and Life Sciences LeadersMay 25, 2024 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by BNP Paribas Financial MarketsBNP Paribas Financial Markets cut its position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 60.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 215,011 shares of the company's stock after sellingMay 23, 2024 | msn.comUnique gene editing drug could treat genetic blindness, but how it compares to existing therapiesMay 23, 2024 | americanbankingnews.comAnalyzing Editas Medicine (NASDAQ:EDIT) & LENZ Therapeutics (NASDAQ:LENZ)May 22, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Stock Price Up 11.6%Editas Medicine (NASDAQ:EDIT) Stock Price Up 11.6%May 16, 2024 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by BrokeragesEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to theMay 15, 2024 | seekingalpha.comEditas Medicine: Promising Milestone Achieved But Be PatientMay 15, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Shares Gap Up on Insider Buying ActivityEditas Medicine (NASDAQ:EDIT) Shares Gap Up on Insider Buying ActivityMay 15, 2024 | insidertrades.comEditas Medicine, Inc. (NASDAQ:EDIT) Director Jessica Hopfield Acquires 45,000 SharesMay 14, 2024 | finance.yahoo.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)May 14, 2024 | marketbeat.comInsider Buying: Editas Medicine, Inc. (NASDAQ:EDIT) Director Buys 45,000 Shares of StockEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) Director Jessica Hopfield acquired 45,000 shares of the stock in a transaction on Monday, May 13th. The stock was bought at an average price of $5.64 per share, with a total value of $253,800.00. Following the transaction, the director now directly owns 67,700 shares of the company's stock, valued at approximately $381,828. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 14, 2024 | globenewswire.comEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in JuneMay 12, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth PotentialMay 10, 2024 | markets.businessinsider.comEditas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal PrudenceMay 10, 2024 | globenewswire.comEditas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual MeetingMay 9, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Price Target Cut to $15.00Citigroup reduced their price objective on Editas Medicine from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday.May 9, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPSEditas Medicine (NASDAQ:EDIT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.13). The firm had revenue of $1.10 million during the quarter, compared to the consensus estimate of $11.14 million. Editas Medicine had a negative return on equity of 42.95% and a negative net margin of 196.12%. The firm's revenue for the quarter was down 88.9% compared to the same quarter last year. During the same period last year, the company earned ($0.71) EPS.May 9, 2024 | fool.com1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?May 9, 2024 | markets.businessinsider.comEditas Medicine’s Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy RatingMay 9, 2024 | markets.businessinsider.comBuy Rating for Editas Medicine: Promising Trials and Solid Financial Footing Propel Growth OutlookMay 9, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Lifted to Equal Weight at Morgan StanleyMorgan Stanley raised Editas Medicine from an "underweight" rating to an "equal weight" rating and set a $7.00 price target for the company in a report on Thursday.May 9, 2024 | finance.yahoo.comEditas Medicine First Quarter 2024 Earnings: Misses ExpectationsMay 8, 2024 | washingtonpost.comEditas: Q1 Earnings SnapshotMay 8, 2024 | investorplace.comEDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comEditas Medicine Announces First Quarter 2024 Results and Business UpdatesMay 7, 2024 | msn.comGene Editing Improves Vision in Rare and Devastating Retinal DisorderMay 7, 2024 | msn.comEditas Medicine Q1 2024 Earnings PreviewMay 7, 2024 | markets.businessinsider.comWhat Wall Street expects from Editas Medicine's earningsMay 6, 2024 | msn.comCRISPR gene editing shows promise for treating individuals with a form of inherited blindnessMay 6, 2024 | msn.comClinical trial shows measurable improvement in inherited blindness after gene therapyMay 5, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%May 3, 2024 | marketbeat.comEditas Medicine (EDIT) to Release Earnings on WednesdayEditas Medicine (NASDAQ:EDIT) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 2, 2024 | globenewswire.comEditas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor EventsMay 2, 2024 | uk.finance.yahoo.comStocks search for direction ahead of Fed rate decisionMay 1, 2024 | msn.comEditas, Bristol Myers extend T cell therapy collaborationMay 1, 2024 | globenewswire.comEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell CollaborationApril 29, 2024 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Sees Large Increase in Short InterestEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 18,760,000 shares, a growth of 14.7% from the March 31st total of 16,360,000 shares. Based on an average trading volume of 1,910,000 shares, the short-interest ratio is presently 9.8 days.April 26, 2024 | marketbeat.comZacks Research Analysts Boost Earnings Estimates for Editas Medicine, Inc. (NASDAQ:EDIT)Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Investment analysts at Zacks Research increased their Q3 2025 EPS estimates for shares of Editas Medicine in a research note issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earninApril 24, 2024 | investing.comEditas to present gene editing advancements at ASGCTApril 22, 2024 | globenewswire.comEditas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual MeetingApril 20, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Sells 177,556 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)Mirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 47.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 197,971 shares of the company's stock after selling 177,556 shares durinApril 18, 2024 | investing.comEditas Medicine Inc (EDIT)April 15, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Hits New 52-Week Low at $6.05Editas Medicine (NASDAQ:EDIT) Reaches New 52-Week Low at $6.05April 14, 2024 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Short Interest UpdateEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 16,360,000 shares, an increase of 17.4% from the March 15th total of 13,930,000 shares. Based on an average trading volume of 1,840,000 shares, the short-interest ratio is presently 8.9 days. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s arrest is phase one (Ad)In this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. EDIT Media Mentions By Week EDIT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼0.210.78▲Average Medical News Sentiment EDIT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼94▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Voyager Therapeutics News Today Allogene Therapeutics News Today Ocugen News Today Fate Therapeutics News Today TScan Therapeutics News Today Lexeo Therapeutics News Today C4 Therapeutics News Today Adaptive Biotechnologies News Today Alector News Today Sutro Biopharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
